Dr. Martens (LON:DOCS) Insider Ije Nwokori Acquires 219 Shares

Dr. Martens plc (LON:DOCS) insider Ije Nwokori acquired 219 shares of Dr. Martens stock in a transaction that occurred on Wednesday, February 11th. The shares were purchased at an average cost of GBX 69 per share, with a total value of £151.11.

Ije Nwokori also recently made the following trade(s):

• On Tuesday, January 13th, Ije Nwokori acquired 192 shares of Dr. Martens stock. The shares were purchased at an average price of GBX 78 per share, with a total value of £149.76.
• On Thursday, December 11th, Ije Nwokori bought 197 shares of Dr. Martens stock. The shares were purchased at an average price of GBX 76 per share, with a total value of £149.72.

Dr. Martens Stock Up 2.0%

Shares of Dr. Martens stock opened at GBX 68.62 on Friday. The stock has a market cap of £663.29 million, a price-to-earnings ratio of 40.37, a price-to-earnings-growth ratio of 6.40 and a beta of 0.11. Dr. Martens plc has a twelve month low of GBX 43.02 and a twelve month high of GBX 100.87. The company has a current ratio of 2.85, a quick ratio of 1.13 and a debt-to-equity ratio of 127.27. The company has a fifty day moving average price of GBX 73.90 and a 200 day moving average price of GBX 82.17.

Dr. Martens (LON:DOCS) last issued its quarterly earnings data on Thursday, November 20th. The company reported GBX (0.90) earnings per share for the quarter. Dr. Martens had a net margin of 7.89% and a return on equity of 18.91%. Equities research analysts forecast that Dr. Martens plc will post 2.5809394 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

DOCS has been the topic of several recent analyst reports. Berenberg Bank reaffirmed a “buy” rating on shares of Dr. Martens in a research note on Tuesday, January 27th. Royal Bank Of Canada restated a “sector perform” rating on shares of Dr. Martens in a research note on Tuesday, February 3rd. Finally, Peel Hunt reiterated a “buy” rating on shares of Dr. Martens in a report on Thursday, November 20th. Two equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of GBX 6,000.

Dr. Martens Company Profile

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.